- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Mylan launches generic version of Detrol LA
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
PITTSBURGH — Generic drug maker Mylan has settled a patent litigation suit with Pfizer concerning a drug for treating bladder disorders, Mylan said Friday.
The Pittsburgh-based company said it settled with Pfizer over its generic version of Detrol LA (tolterodine tartrate) extended-release capsules in the 2-mg and 4-mg strengths. The drug is used to treat urge urinary incontinence, urgency and frequency.
Under the terms of the settlement, Mylan can launch its drug starting in 2014, pending final approval by the Food and Drug Administration, either as a generic drug or as an authorized generic, which is a branded drug marketed under its generic name at a reduced price.
The drug had sales of $599 million during the 12-month period ended in June, according to IMS Health.